North East and North Cumbria
ICS Formulary
ICS Formulary
8 Malignant disease and immunosuppression
08-03-04-02 Gonadorelin analogues
Clinicians are encouraged to prescribe the least expensive product that is clinically appropriate.
| Leuprorelin Acetate |
|
First Choice
|
|
|
| Triptorelin |
|
First Choice
|
|
|
|
| Degarelix |
|
First Choice
|
|
 NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
|
|
Links
- Cancer Drug Fund List
- MHRA Drug Safety Update (December 2017): Radium-223 dichloride (Xofigo▼): do not use in combination with abiraterone and prednisone/prednisolone, following clinical trial signal of increased risk of death and fractures
- NICE NG131: Prostate cancer: diagnosis and management
- NICE TA259: Abiraterone for castration resistant prostate cancer
- NICE TA316: Enzalutamide for prostate cancer
- NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
- NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
- NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
- NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
- NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
- NICE TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
- NICE TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
- NICE TA741: Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
- NICE TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
- NICE TA995 : Relugolix for treating hormone-sensitive prostate cancer
- Northern Cancer Alliance
Northern England Clinical Networks Palliative and End of Life Care Guidelines